Elevance Health held adjusted earnings outlook at at least $27.00 per share

According to the company, Elevance Health continued to expect adjusted shareholders' earnings to be at least $27.00 per diluted share. That outlook excluded approximately $6.90 per diluted share of net unfavorable items. The company also reaffirmed full year 2026 benefit expense ratio guidance of 90.2% plus or minus 50 basis points.

For investors, the distinction separated one-off pressure from the operating picture the company wanted to emphasize. Excluding the unfavorable items left the underlying expectation unchanged, which kept attention on medical costs rather than accounting effects. That framing helped readers judge performance on a comparable basis.

According to the company, the update was filed as Form 8-K and was furnished under Item 7.01 - Regulation FD Disclosure. The registrant's exact name was Elevance Health Inc, and its Common Stock, Par Value $0.01 traded under symbol ELV on NYSE. The report listed September 10, 2026 as Date of Report.

Officers of Elevance Health expected to speak with investors and analysts over the next several weeks. The company said its outlook did not include any other adjustment items beyond those reported in its second quarter 2026 earnings. Those meetings gave investors a chance to ask about the earnings outlook and the benefit expense ratio guidance.